Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 1
2008 2
2009 1
2010 2
2011 1
2012 1
2013 1
2016 2
2017 2
2018 1
2019 4
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Chronic Inflammation Might Protect Hemodialysis Patients From Severe COVID-19.
Prietl B, Odler B, Kirsch AH, Artinger K, Eigner M, Schmaldienst S, Pfeifer V, Stanzer S, Eberl A, Raml R, Pieber T, Rosenkranz AR, Brodmann M, Eller P, Eller K. Prietl B, et al. Among authors: stanzer s. Front Immunol. 2022 Feb 21;13:821818. doi: 10.3389/fimmu.2022.821818. eCollection 2022. Front Immunol. 2022. PMID: 35265078 Free PMC article.
GIRK1 triggers multiple cancer-related pathways in the benign mammary epithelial cell line MCF10A.
Schratter G, Scheruebel S, Langthaler S, Ester K, Pelzmann B, Ghaffari-Tabrizi-Wizsy N, Rezania S, Gorischek A, Platzer D, Zorn-Pauly K, Ahammer H, Prokesch A, Stanzer S, Devaney TTJ, Schmidt K, Jahn SW, Prassl R, Bauernhofer T, Schreibmayer W. Schratter G, et al. Among authors: stanzer s. Sci Rep. 2019 Dec 17;9(1):19277. doi: 10.1038/s41598-019-55683-w. Sci Rep. 2019. PMID: 31848385 Free PMC article.
Patterns of Peripheral Blood B-Cell Subtypes Are Associated With Treatment Response in Patients Treated With Immune Checkpoint Inhibitors: A Prospective Longitudinal Pan-Cancer Study.
Barth DA, Stanzer S, Spiegelberg JA, Bauernhofer T, Absenger G, Szkandera J, Gerger A, Smolle MA, Hutterer GC, Ahyai SA, Madl T, Posch F, Riedl JM, Klec C, Jost PJ, Kargl J, Stradner MH, Pichler M. Barth DA, et al. Among authors: stanzer s. Front Immunol. 2022 Apr 1;13:840207. doi: 10.3389/fimmu.2022.840207. eCollection 2022. Front Immunol. 2022. PMID: 35432362 Free PMC article.
Evaluation of autoantibodies as predictors of treatment response and immune-related adverse events during the treatment with immune checkpoint inhibitors: A prospective longitudinal pan-cancer study.
Barth DA, Stanzer S, Spiegelberg J, Bauernhofer T, Absenger G, Posch F, Lipp R, Halm M, Szkandera J, Balic M, Gerger A, Smolle MA, Hutterer GC, Klec C, Jost PJ, Kargl J, Stradner M, Pichler M. Barth DA, et al. Among authors: stanzer s. Cancer Med. 2022 Aug;11(16):3074-3083. doi: 10.1002/cam4.4675. Epub 2022 Mar 16. Cancer Med. 2022. PMID: 35297215 Free PMC article.
Immune cell landscape in therapy-naïve squamous cell and adenocarcinomas of the lung.
Brcic L, Stanzer S, Krenbek D, Gruber-Moesenbacher U, Absenger G, Quehenberger F, Valipour A, Lindenmann J, Stoeger H, Al Effah M, Fediuk M, Balic M, Popper HH. Brcic L, et al. Among authors: stanzer s. Virchows Arch. 2018 Apr;472(4):589-598. doi: 10.1007/s00428-018-2326-0. Epub 2018 Mar 8. Virchows Arch. 2018. PMID: 29520483 Free PMC article.
MiR-1287-5p inhibits triple negative breast cancer growth by interaction with phosphoinositide 3-kinase CB, thereby sensitizing cells for PI3Kinase inhibitors.
Schwarzenbacher D, Klec C, Pasculli B, Cerk S, Rinner B, Karbiener M, Ivan C, Barbano R, Ling H, Wulf-Goldenberg A, Stanzer S, Rinnerthaler G, Stoeger H, Bauernhofer T, Haybaeck J, Hoefler G, Jahn SW, Parrella P, Calin GA, Pichler M. Schwarzenbacher D, et al. Among authors: stanzer s. Breast Cancer Res. 2019 Feb 1;21(1):20. doi: 10.1186/s13058-019-1104-5. Breast Cancer Res. 2019. PMID: 30709367 Free PMC article.
20 results